Physician profile
G Bigley
NPI 1811947914
$132,647.13
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $26K · 2021: $22K · 2022: $4,912 · 2023: $20K · 2024: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $6,064 · Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,587.00 |
| Travel and Lodging | $6,064.00 |
| Food and Beverage | $995.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $62,902.01 | 2019-2024 | Vumerity |
| Genzyme Corporation | $28,092.93 | 2019-2023 | |
| Celgene Corporation | $18,503.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $14,210.73 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $4,308.09 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $3,934.27 | 2019-2022 | |
| Emd Serono, INC. | $476.95 | 2019-2023 | Mavenclad |
| Genentech USA, INC. | $72.76 | 2024 | |
| Janssen Pharmaceuticals, INC | $65.00 | 2022 | |
| Horizon Therapeutics Plc | $53.02 | 2022 | |
| Banner Life Sciences, LLC | $15.30 | 2022 | |
| Abbvie INC. | $13.06 | 2023 | Ubrelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw G Bigley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.